Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar;67(3):1127-1131.
doi: 10.1002/hep.29509. Epub 2018 Jan 24.

A research agenda for curing chronic hepatitis B virus infection

Harvey Alter  1 , Timothy Block  2 , Nathaniel Brown  2 , Alan Brownstein  2 , Carol Brosgart  3 , Kyong-Mi Chang  4 , Pei-Jer Chen  5 , Francis V Chisari  6 , Chari Cohen  2 , Hashem El-Serag  7 , Jordan Feld  8 , Robert Gish  2   9 , Jeffrey Glenn  10 , Tim Greten  11 , Haitao Guo  12 , Ju-Tao Guo  2 , Yujin Hoshida  13 , Jianming Hu  14 , Kris V Kowdley  15 , Wenhui Li  16 , Jake Liang  17 , Stephan Locarnini  18 , Anna S Lok  19 , William Mason  20 , Brian McMahon  21 , Anand Mehta  22 , Robert Perrillo  23 , Peter Revill  18 , Charles M Rice  24 , JoAnn Rinaudo  11 , Raymond Schinazi  25 , Christoph Seeger  20 , Kirty Shetty  26 , John Tavis  27 , Fabien Zoulim  28
Affiliations

A research agenda for curing chronic hepatitis B virus infection

Harvey Alter et al. Hepatology. 2018 Mar.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
HBV life cycle, emphasizing opportunities to suppress viral cccDNA and restore immune control. Host and viral functions that could be exploited for therapeutic purposes are illustrated, beginning with binding of the virus to the sodium–taurocholate cotransporting polypeptide receptor on hepatocytes (1), followed by translocation of the nucleocapsid to the nucleus and formation of cccDNA (2) and synthesis steps (3,4), leading to either egress (6) of newly formed virions or recycling of cccDNA‐containing nucleocapsids to the nucleus (7). Opportunities for cccDNA suppression and immune control are categorized as either acting upon the viral gene products (white boxed text) or acting upon host innate and adaptive immune systems (green boxed text), noting that in many cases these different pathways overlap. Humoral responses are also indicated (Abs). Orange, red, and brown circles indicate small, medium, and large hepatitis B surface proteins, respectively; yellow triangle (core protein), blue circle (pol), “X” (x protein), red semicircles, cccDNA and black line, HBV 3.2 kb and subgenomic HBV RNA; 22‐nM in diameter spherical and rod‐shaped subviral envelope particles and infectious 42‐nM virions are also illustrated. The examples of virus life cycle steps and immune modulators are representative and not comprehensive. Toll‐like receptor 3 is shown because it is present in hepatocytes, but other toll‐like receptors may also be exploited therapeutically. Abbreviations: Abs, antibodies; CTLA4, cytotoxic T lymphocyte antigen 4; IFNAR, type 1 interferon receptor; NTCP, sodium–taurocholate cotransporting polypeptide; PD1, programmed death 1; TLR3, Toll‐like receptor 3.
See this image and copyright information in PMC

References

    1. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29‐60. - PubMed
    1. McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis 2010;14:381‐396. - PubMed
    1. National Academies of Sciences, Engineering, and Medicine. 2016. Eliminating the public health problem of hepatitis B and C in the United States: Phase one report. Washington, DC: The National Academies Press. doi: 10.17226/23407. - DOI - PubMed
    1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age‐specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212‐2219. - PubMed
    1. World Health Organization . Combating hepatitis B and C to reach elimination by 2030: An advocacy brief. Geneva, Switzerland: World Health Organization; 2016. http://apps.who.int/iris/bitstream/10665/206453/1/WHO_HIV_2016.04_eng.pd...